Goserelin, sold under the brand name Zoladex, has been a cornerstone of hormone therapy for more than three decades, and it remains one of the most consistently prescribed LHRH agonists across Indian oncology and gynaecology practices in 2026. Despite how established the molecule is, hospital pharmacists and procurement teams still raise the same set of practical questions year after year — which strength to stock, how dosing intervals actually work, and how to verify that a batch reaching their facility is genuine. This guide works through all of it in one place.

What Is Zoladex (Goserelin) and How Does It Work?

Goserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH). When administered continuously via a slow-release subcutaneous depot, it initially stimulates and then suppresses the pituitary gland’s release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). The downstream effect is a sharp drop in testosterone in men and estrogen in women — a state often referred to clinically as “medical castration.”

This mechanism is what makes goserelin useful across a surprisingly broad range of hormone-sensitive conditions, despite being a single molecule with a single delivery mechanism.

Clinical Uses of Zoladex in India

1. Advanced and Locally Advanced Prostate Cancer

Zoladex is widely used as first-line androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer, often in combination with anti-androgens such as bicalutamide during the initial weeks to manage the testosterone surge (“flare”) that can occur with GnRH agonists. It is also frequently used as adjuvant therapy alongside radiotherapy in locally advanced disease, reflecting protocols established in landmark trials from the early 2000s that demonstrated significant survival benefit when ADT was combined with radiation in high-risk localized prostate cancer.

2. Hormone Receptor-Positive Early Breast Cancer

In pre-menopausal women with hormone receptor-positive breast cancer, ovarian suppression with goserelin — usually paired with tamoxifen or an aromatase inhibitor — is a standard option, particularly in younger patients where chemotherapy-induced ovarian failure cannot be relied upon. This approach is grounded in trial data showing that adding ovarian suppression to standard endocrine therapy improves outcomes in higher-risk pre-menopausal patients.

3. Endometriosis and Uterine Fibroids

Short courses of goserelin are used pre-operatively to shrink fibroids and reduce vascularity before surgery, and to manage pain in endometriosis by inducing a temporary low-estrogen state.

4. Fertility Preservation

Goserelin is sometimes used off-label alongside chemotherapy in young women to help preserve ovarian function, although this remains a more specialised and less universally adopted application.

Zoladex Dosing — 3.6 mg vs 10.8 mg Explained

A common point of confusion among newer pharmacy staff is the relationship between the two depot strengths. They are not interchangeable doses of the same schedule — they are two distinct formulations engineered for different release profiles.

The 10.8 mg long-acting (LA) formulation is not simply three 3.6 mg doses combined — it uses a different polymer matrix designed to release goserelin steadily over 12 weeks. This matters clinically: switching a patient from monthly to 3-monthly dosing (or vice versa) requires recalculating the treatment calendar from the date of the last monthly dose, not from an arbitrary point.

For prostate cancer patients on long-term ADT — often years of continuous treatment — the 10.8 mg formulation has become the preferred choice in most Indian oncology centres simply because it reduces hospital visits from thirteen a year down to four, which matters considerably for elderly patients and for centres managing high patient volumes.

Administration Notes for Hospital and Clinic Staff

• Both formulations are administered as a subcutaneous injection into the anterior abdominal wall, typically by a trained nurse or physician — not self-administered.
• The pre-filled syringe applicator should be inspected for visible damage before use; bent needles or compromised seals should never be used regardless of how close the appointment time is.
• Patients beginning ADT for prostate cancer should be counselled about the initial testosterone surge and, where clinically appropriate, co-prescribed a short course of anti-androgen cover during the first weeks of treatment.
• Bone mineral density should be monitored in patients on long-term goserelin therapy, given the known association between prolonged hormone suppression and reduced bone density.

Sourcing Genuine Zoladex in India — What Hospitals Should Check

Because goserelin carries real clinical weight in oncology protocols, sourcing from a verified channel matters as much as correct dosing. When procuring Zoladex, hospital and pharmacy teams should verify:

• Batch number and expiry clearly printed and matching the accompanying documentation
• Manufacturer packaging and holography consistent with AstraZeneca’s current Indian packaging
• Cold chain compliance — goserelin depots must be maintained between 2°C and 8°C from the point of dispatch through to delivery; any visible signs of temperature excursion (condensation inside packaging, deformed applicators) should be treated as a red flag
• Complete paperwork — invoice, batch certificate, and import documentation where applicable, especially for facilities procuring larger institutional quantities

How A.K. Pharma Supplies Zoladex

A.K. Pharma is a licensed specialty medicine distributor in Delhi supplying genuine Zoladex (Goserelin) — both the 3.6 mg and 10.8 mg long-acting strengths — to hospitals, oncology centres, and pharmacies across India. As a distributor focused specifically on specialty and imported medicines, A.K. Pharma maintains certified cold chain infrastructure from procurement through last-mile hospital delivery, along with complete batch documentation for every shipment.

Hospitals and clinics that work with multiple oncology and hormone therapy medicines often find it more efficient to consolidate sourcing through a single specialty distributor rather than managing separate vendor relationships — A.K. Pharma also supplies related hormone therapy and oncology support medicines including Firmagon (Degarelix), used as an alternative GnRH antagonist in prostate cancer, and Prolia (Denosumab), commonly co-prescribed for bone health support in patients on long-term ADT.

View the full Zoladex product page →

Frequently Asked Questions